Clinical Trial

Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 8, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To assess the efficacy and safety of using recombinant humanized anti-CD25 monoclonal antibody injection as a prophylactic strategy for reducing the incidence of severe acute graft-versus-host disease (aGVHD) in adult patients at intermediate to high risk, as predicted by the dynamic aGVHD Onset Anticipation Tianjin (daGOAT) model, following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-11.
Status change: Not Yet Recruiting → Recruiting 2025-08-04
Trial Details
NCT Number NCT06880419
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Acute Graft-versus-Host Disease
Enrollment 174 participants
Start Date 2025-03-03
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-08